Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


30.10.2017

1 Am J Surg Pathol
1 Anticancer Res
3 BJU Int
1 Chin J Cancer
5 Clin Genitourin Cancer
1 Hinyokika Kiyo
6 J Urol
1 Mayo Clin Proc
1 Med Oncol
1 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg Pathol

  1. BORHAN WM, Cimino-Mathews AM, Montgomery EA, Epstein JI, et al
    Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
    Am J Surg Pathol. 2017;41:1570-1575.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. SCHINZARI G, Monterisi S, Pierconti F, Nazzicone G, et al
    Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Anticancer Res. 2017;37:6453-6458.
    PubMed     Text format     Abstract available


    BJU Int

  3. HUDDART RA, Birtle A, Maynard L, Beresford M, et al
    Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    BJU Int. 2017;120:639-650.
    PubMed     Text format     Abstract available

  4. AHMADI N, Clifford TG, Miranda G, Cai J, et al
    Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion.
    BJU Int. 2017;120:689-694.
    PubMed     Text format     Abstract available

  5. XIA L, Taylor BL, Newton AD, Malhotra A, et al
    Early Discharge and Post-Discharge Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14058.
    PubMed     Text format     Abstract available


    Chin J Cancer

  6. BI X, Wu Z, Han H, Zhou F, et al
    Clinical comparison of patients with benign urachal masses versus urachal carcinomas.
    Chin J Cancer. 2017;36:2.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  7. MOSCHINI M, Soria F, Klatte T, Wirth GJ, et al
    Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.
    Clin Genitourin Cancer. 2017;15:e267-e273.
    PubMed     Text format     Abstract available

  8. SINGH R, Ansari JA, Maurya N, Mandhani A, et al
    Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2017;15:e187-e197.
    PubMed     Text format     Abstract available

  9. CARAS RJ, Lustik MB, Kern SQ, McMann LP, et al
    Preoperative Albumin Is Predictive of Early Postoperative Morbidity and Mortality in Common Urologic Oncologic Surgeries.
    Clin Genitourin Cancer. 2017;15:e255-e262.
    PubMed     Text format     Abstract available

  10. MONN MF, Jaqua KR, Bihrle R, Cheng L, et al
    Primary Choriocarcinoma of the Bladder: A Case Report and Review of Literature.
    Clin Genitourin Cancer. 2017;15:188-191.
    PubMed     Text format     Abstract available

  11. KHORRAMI MH, Javid A, Izadpanahi MH, Alizadeh F, et al
    Efficacy of Long-Acting Octreotide on Reducing Mucus Production in Patients With Ileal Neobladder.
    Clin Genitourin Cancer. 2017;15:e9-e13.
    PubMed     Text format     Abstract available


    Hinyokika Kiyo

  12. UEMURA K, Namura K, Umemoto S, Matsubara O, et al
    [A Case of Squamous Cell Carcinoma in Bladder Diverticulum Producing Granulocyte Colony Stimulating Factor].
    Hinyokika Kiyo. 2017;63:211-215.
    PubMed     Text format     Abstract available


    J Urol

  13. ATALA A
    Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer.
    J Urol. 2017;198:983-985.
    PubMed     Text format    

  14. ATALA A
    Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
    J Urol. 2017;198:984-985.
    PubMed     Text format    

  15. CHANG SS
    Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2017;198:979-980.
    PubMed     Text format    

  16. ATALA A
    Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:985.
    PubMed     Text format    

  17. WALLACE E, Higuchi R, Satya M, McCann L, et al
    Development of a 90-minute integrated non-invasive urinary assay for bladder cancer detection.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77760-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  18. CHANG SS
    Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2017;198:978-980.
    PubMed     Text format    


    Mayo Clin Proc

  19. GIRIDHAR KV, Kohli M
    Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Mayo Clin Proc. 2017;92:1564-1582.
    PubMed     Text format     Abstract available


    Med Oncol

  20. HAKOZAKI K, Kikuchi E, Fukumoto K, Shirotake S, et al
    Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy.
    Med Oncol. 2017;34:187.
    PubMed     Text format     Abstract available


    World J Urol

  21. BACH T, Bastian PJ, Blana A, Kaminsky A, et al
    Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    World J Urol. 2017;35:737-744.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: